Sangamo Therapeutics, Inc

Ownership Transactions Reported by 21 Insiders

Symbol
SGMO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
501 Canal Blvd., Richmond, CA

There are no Buy or Sell transactions made by insiders since 10/5/2024

Sangamo Therapeutics, Inc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Biogen Inc. 10%+ Owner $6.75M Sep 26, 2023
Sandy Macrae PRESIDENT, CEO AND DIRECTOR, Director $1.28M Aug 24, 2025
Nathalie Dubois-Stringfellow Svp Chief Development Officer $449K Aug 24, 2025
Scott B. Willoughby Svp, Chief Legal Officer, Secy $439K Aug 24, 2025
Prathyusha Duraibabu Svp, Chief Financial Officer $436K Aug 24, 2025
Amy Pooler Vp, Head Of Research $167K Aug 24, 2024
Gregory D. Davis Head of Research & Technology $118K Aug 24, 2025
David Mark McClung EVP, Chief Operating Officer $81.2K Nov 25, 2023
Rolf Andrew Ramelmeier EVP, Technical Operations $65.5K May 25, 2023
Jason D. Fontenot SVP, Chief Scientific Officer $52.1K Nov 25, 2023
Parker H Stewart Director $51.8K Jun 12, 2025
Karen L. Smith Director $47K Jun 12, 2025
James R. Meyers Director $45.8K Jun 12, 2025
Robert Carey Director $45.8K Jun 12, 2025
Kenneth J. Hillan Director $45.8K Jun 12, 2025
John Markels Director $44.3K Jun 12, 2025
Courtney Beers Director $38K Jun 12, 2025
Margaret Horn Director $38K Jun 12, 2025
Robert J. Schott SVP, Head of Development $28.9K Feb 25, 2022
Joseph S. Zakrzewski Director $23.2K Feb 25, 2022
Saira Ramasastry Director $13.6K Feb 25, 2022

Recent Insider Transactions by Companies or Individuals for Sangamo Therapeutics, Inc

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.